In our oncology focus month, Ryan McGuire takes a look at the impact of clinical development on cancer drug ... phase 1, phase 2 and phase 3 clinical trial." Based on the report's trial data, it ...

Recursion Pharmaceuticals could benefit from FDA’s AI shift despite risks, with scalable tech and long-term potential. Find ...

Pre-Clinical Drug Discovery Services Market to grow through 2035, driven by rising chronic diseases and increased outsourcing of early-stage R&D.

Andrei Georgescu of Vivodyne discusses key advantages of its humanized drug testing platform and the impact of the FDA’s ...

The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

Diabetic macular edema is a complication that develops from diabetic retinopathy, a widespread consequence of diabetes and a ...

Artificial Intelligence (AI) is no longer a futuristic idea in healthcare; it is reshaping the industry right now, and 2025 ...

Amgen AMGN reported first-quarter 2025 adjusted earnings of $4.90 per share, which beat the Zacks Consensus Estimate of $4.16 ...

Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease remains on track for topline data readout in the second quarter 2025 - - Tourmaline ...

Launched Neurosterix with Perceptive Advisors, raising USD 65 million in Series A to advance preclinical portfolioIndivior selected GABAB PAM drug candidate and started IND enabling studies for develo ...

In 2014, the clinical development success rate stood at 10.4%; just over one in every 10 drugs that entered a Phase I clinical ... clinical trials in a more cost-effective manner.

Health believe that the United States Agency for International Development (USAID ... thing is that we don't get malaria drugs at the primary healthcare centres. Most times, we have to get them at a ...